Table 3.

Response by Biomarker Status

Factor	% of Patients by Response and Treatment Arm
	CR + PR		CR + PR + SD
	Erlotinib (n = 69)	CP + Intercalated Erlotinib (n = 67)*	Erlotinib (n = 69)	CP + Intercalated Erlotinib (n = 67)*
Overall	11.6	22.4	46.4	71.6
EGFR by IHC status
Positive	9.4	21.3	45.3	72.1
Negative	33.3	33.3	66.7	66.7
EGFR by FISH status
Positive	18.9	25.7	54.1	74.3
Negative	3.3	18.8	36.7	68.8
EGFR mutation status
Mutation	53.8	36.4	84.6	81.8
Activating mutation	66.7	33.3	100.0	66.7
Other mutation	25.0	40.0	50.0	100.0
No mutation	0	22.7	35.6	68.2
KRAS mutation status
Mutation	0	20.0	30.8	53.3
No mutation	15.7	24.0	52.9	78.0
E-cadherin
High	8.0	28.6	52.0	76.2
Low	18.2	16.0	36.4	56.0
Vimentin
High	15.0	27.3	40.0	100.0
Low	10.7	21.2	42.9	57.6

Abbreviations: CR, complete response; PR, partial response; SD, stable disease; CP, carboplatin/paclitaxel; IHC, immunohistochemistry; FISH, fluorescent in situ hybridization.

^*One patient on the CP + intercalated erlotinib arm had no measurable disease at baseline and was nonevaluable for response.